|
Polymorphisms
|
HAM/TSP
|
Asymptomatic
| | |
|---|
|
n (%)
|
n (%)
|
OR (IC:95%)
|
p-value
|
|---|
|
TNFA-308G/A
|
|
GG
|
55 (82.1)
|
69 (83.1)
|
1
|
0.98
|
|
GA
|
12 (17.9)
|
13 (15.7)
|
1.16 (0.48–2.75)
| |
|
AA
|
0
|
1 (1.2)
|
0 (NA)
| |
|
GG (low)
|
55 (82.1)
|
69 (83.1)
|
1
|
1
|
|
GA + AA (high)
|
12 (17.9)
|
14 (16.9)
|
1.08 (0.45–2.52)
| |
|
AA
|
0
|
1 (1.2)
|
1
|
1
|
|
GA + GG
|
67 (100)
|
82 (98.8)
|
0 (NA)
| |
|
Alleles
|
|
G
|
122 (91.0)
|
151 (91.0)
|
1
|
1
|
|
A
|
12 (9.0)
|
15 (9.0)
|
0.99 (0.44–2.19)
| |
|
IL6-174G/C
|
|
GG
|
48 (71.6)
|
56 (68.3)
|
1
|
0.88
|
|
GC
|
16 (23.9)
|
24 (29.3)
|
0.78 (0.37–1.62)
| |
|
CC
|
3(4.5)
|
2 (2.4)
|
1.75 (0.28–13.7)
| |
|
CC (low)
|
3 (4.5)
|
2 (2.4)
|
1
|
0.66
|
|
GC + GG (high)
|
64 (95.5)
|
80 (97.6)
|
0.53 (0.07–3.31)
| |
|
GG
|
48 (71.6)
|
56 (68.3)
|
1
|
0.79
|
|
GC + CC
|
19 (28.4)
|
26 (31.7)
|
0.85 (0.42–172)
| |
|
Alleles
|
|
G
|
112(83.6)
|
136 (82.9)
|
1
|
1
|
|
C
|
22 (16.4)
|
28 (17.1)
|
0.95 (0.51–1.76)
| |
|
IFNG + 874 T/A
|
|
AA (low)
|
34 (50.7)
|
34 (43.6)
|
1
|
0.86
|
|
AT (intermediate)
|
26 (38.8)
|
40 (51.3)
|
0.65 (0.33–1.29)
| |
|
TT (high)
|
7(10.4)
|
4 (5.1)
|
1.75 (0.48–7.20)
| |
|
AA
|
34 (50.7)
|
34 (43.6)
|
1
|
0.49
|
|
AT+TT
|
33 (49.3)
|
44 (56.4)
|
0.75 (0.39–1.44)
| |
|
TT
|
7 (10.4)
|
4 (5.1)
|
1
|
0.35
|
|
AT+AA
|
60 (89.6)
|
74 (94.9)
|
0.46 (0.12–1.61)
| |
|
Alleles
|
|
A
|
94 (70.1)
|
108 (69.2)
|
1
|
0.97
|
|
T
|
40 (29.9)
|
48 (30.8)
|
0.96 (0.58–1.58)
| |
- HAM/TSP HTLV-1 associated myelopathy tropical spastic paraparesis, Asymptomatic HTLV-1 patients, OR odds ration with confident interval, Chi-square 2 × 2 or 3 × 2 contingent tables, Fisher exact or Cochran-Armitage tests
